WP-1066

DB12679InvestigationalSmall molecule

WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.

Chemical structure of WP-1066
Formula / weight
C17H14BrN3O · 356.223 g/mol (avg)
Also known as
(E)-3-(6-Bromo-pyridin-2-yl)-2-cyano-N-((S)-1-phenyl-ethyl)-acryl amide · 2-PROPENAMIDE, 3-(6-BROMO-2-PYRIDINYL)-2-CYANO-N-((1S)-1-PHENYLETHYL)-, (2E)-
Code names
WP-1066

Resolves to

Compound
UNII63V8AIE65TCAS857064-38-1ChEMBLCHEMBL1923234PubChem11210478
Structure
InChIKeyVFUAJMPDXIRPKO-LQELWAHVSA-NSMILESC[C@H](NC(=O)C(=C\C1=CC=CC(Br)=N1)\C#N)C1=CC=CC=C1
Targets
P40763STAT3

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with WP-1066, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In